Original Article

Treating depression with a smartphone-delivered self-help cognitive behavioral therapy for insomnia: a parallel-group randomized controlled trial

Christian S. Chan[1] [ID], Christy Y. F. Wong[1] [ID], Branda Y. M. Yu[1] [ID], Victoria K. Y. Hui[1] [ID], Fiona Y. Y. Ho[2] and Pim Cuijpers[3] [ID]

[1]The University of Hong Kong, Hong Kong; [2]Chinese University of Hong Kong, Hong Kong and [3]Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Abstract

Background. Despite its efficacy in treating comorbid insomnia and depression, cognitive behavioral therapy for insomnia (CBT-I) is limited in its accessibility and, in many countries, cultural compatibility. Smartphone-based treatment is a low-cost, convenient alternative modality. This study evaluated a self-help smartphone-based CBT-I in alleviating major depression and insomnia.

Methods. A parallel-group randomized, waitlist-controlled trial was conducted with 320 adults with major depression and insomnia. Participants were randomized to receive either a 6-week CBT-I via a smartphone application, *proACT-S*, or waitlist condition. The primary outcomes included depression severity, insomnia severity, and sleep quality. The secondary outcomes included anxiety severity, subjective health, and acceptability of treatment. Assessments were administered at baseline, post-intervention (week 6) follow-up, and week 12 follow-up. The waitlist group received treatment after the week 6 follow-up.

Results. Intention to treat analysis was conducted with multilevel modeling. In all but one model, the interaction between treatment condition and time at week 6 follow-up was significant. Compared with the waitlist group, the treatment group had lower levels of depression [Center for Epidemiologic Studies Depression Scale (CES-D): Cohen's $d = 0.86$, 95% CI (-10.11 to -5.37)], insomnia [Insomnia Severity Index (ISI): Cohen's $d = 1.00$, 95% CI (-5.93 to -3.53)], and anxiety [Hospital Anxiety and Depression Scale – Anxiety subscale (HADS-A): Cohen's $d = 0.83$, 95% CI (-3.75 to -1.96)]. They also had better sleep quality [Pittsburgh Sleep Quality Index (PSQI): Cohen's $d = 0.91$, 95% CI (-3.34 to -1.83)]. No differences across any measures were found at week 12, after the waitlist control group received the treatment.

Conclusion. *proACT-S* is an efficacious sleep-focused self-help treatment for major depression and insomnia.

Trial registration. ClinicalTrials.gov, NCT04228146. Retrospectively registered on 14 January 2020. https://clinicaltrials.gov/ct2/show/NCT04228146

Despite its efficacy (Santoft et al., 2019), the accessibility of cognitive behavioral therapy for depression (CBT-D) is often limited by high cost and cultural barriers (Corrigan, Druss, & Perlick, 2014; Shi, Shen, Wang, & Hall, 2020). The preference for self-reliance and stigma in some communities may hamper help-seeking behavior from mental health professionals (e.g. Corrigan et al., 2014; Shi et al., 2020).

In addition to being a common symptom of major depressive disorder (MDD) (McClintock et al., 2011; Tsuno, Besset, & Ritchie, 2005), sleep disturbance, in particular insomnia, also predicts its onset, maintenance, and reoccurrence (Fang, Tu, Sheng, & Shao, 2019; Franzen & Buysse, 2008; Vargas & Perlis, 2020), as well as suicidal ideations and attempts (Harris, Huang, Linthicum, Bryen, & Ribeiro, 2020; Liu et al., 2020). Because of the high comorbidity and the bidirectionality of sleep disturbances and depression, sleep-focused interventions are recommended to be included in the treatment of MDD (Harvey, Murray, Chandler, & Soehner, 2011).

Sleep treatments, in particular CBT for insomnia (CBT-I), are efficacious in alleviating non-sleep symptoms in MDD (Ballesio et al., 2018; Feng, Han, Li, Geng, & Miao, 2020; Ho, Chan, Lo, & Leung, 2020). Among those with comorbid depression and insomnia, improvement in sleep in treatment predicts improvements in depression (Ballesio et al., 2018; Bei et al., 2018).

Sleep-focused treatments are well received (Ho, Chung, Yeung, Ng, & Cheng, 2014), in part because they are perceived by some to be more 'physiological' than 'psychological' (Parker, Cheah, & Roy, 2001). CBT-I can be a preparatory and first-step prior to other more intensive

CAMBRIDGE
UNIVERSITY PRESS

treatments (Baddeley & Gros, 2013; Ho, Yeung, Ng, & Chan, 2016). This study examined the efficacy of a non-assisted smartphone-based CBT-I for those with both depression and insomnia.

Internet-based and smartphone-based CBT-I

There is evidence to suggest that some help-seekers prefer self-help treatments (Hanson, Webb, Sheeran, & Turpin, 2016; Segal, Hodges, & Hardiman, 2002). Self-help treatments can be a particularly viable alternative for those who are reluctant to seek professional help for mental health issues (Chin, Chan, Lam, Lam, & Wan, 2015). Numerous studies have demonstrated the efficacy of self-help CBT-I in treating insomnia (Blom et al., 2015; Horsch et al., 2017; Krieger et al., 2019; Vedaa et al., 2020). Internet-based CBT-I (iCBT-I), in particular, is efficacious in alleviating not just insomnia but also depressive mood in insomnia patients (Ho et al., 2020; Ye et al., 2015). Therapist-guided iCBT-I has been demonstrated to have comparable efficacy for insomnia and depression as therapist-guided iCBT-D in patients suffering from both (Blom, Jernelöv, Rück, Lindefors, & Kaldo, 2017).

The current study further extends this line of work to test the efficacy of iCBT-I in a pure self-help format, without any input from a therapist, for those with both depression and insomnia. Previous trials have demonstrated the efficacy of unguided iCBT on symptoms of depression and insomnia (Christensen et al., 2016; Glozier et al., 2019). The current trial tested the efficacy of a smartphone-based intervention. Given the high accessibility of smartphones, mobile application is a promising platform to deliver timely treatment and professional help for common mental health problems (Economides et al., 2019; Linardon, Cuijpers, Carlbring, Messer, & Fuller-Tyszkiewicz, 2019; Mantani et al., 2017). Considering the increasing smartphone penetration, smartphone self-help application as a flexible and scalable modality of intervention can potentially help lessen the pressing needs for treatments of common mental disorders, including depression and insomnia.

Well-received, low-intensity treatments for depression and insomnia via smartphones might be a convenient and cost-effective adjunct to professional mental health services to overcome the economic, cultural, and personal barriers. This might be particularly pertinent in the context of the unprecedented COVID-19 pandemic. The detrimental impacts of the pandemic on mental health (Salari et al., 2020), especially for those with pre-existing mental disorders (Campion, Javed, Sartorius, & Marmot, 2020), further overwhelm the already overstretched public healthcare system and leave those in need without proper and timely care. Social distancing has made it difficult for those in need of professional help from seeking them. Smartphone-based services might help alleviate such burdens on both patients and their care providers.

Current study

The present study was a two-arm parallel waitlist controlled randomized controlled trial (RCT) investigating the efficacy of *proACT-S*, a smartphone-based, non-assisted self-help CBT-I in patients with comorbid depression and insomnia. The trial was conducted in Hong Kong, where the high smartphone penetration is high (85.8%; Census and Statistics Department, 2017). We hypothesized a greater reduction in both depression and insomnia severity, and improvement in sleep quality in the treatment group compared to waitlist control at the post-treatment follow-up. The waitlist control group was anticipated to have a significant decrease in the outcome measures after receiving the same treatment.

Anxiety symptomology was included as a secondary outcome because of the high comorbidity of anxiety disorders and depressive disorders (Kaufman & Charney, 2000) and the overlap in their symptoms and risk factors, including sleep disturbances. Many have recognized the potentials of sleep treatments, such as CBT-I, and advocate for its use as a transdiagnostic approach to common mental disorders (Harvey et al., 2011). Subjective health was also included as a secondary outcome because of the potential health implications of sleep disturbances (Lekander et al., 2013; Tan et al., 2018).

Treatment expectancy refers to the prognostic expectations about the treatment outcomes, both positive and negative (Goldstein, 1962). Because treatment expectancy of post-treatment outcomes has been found to influence CBT treatment outcomes (Alaoui et al., 2016), we included it as a covariate. We also measured user's acceptability of the treatment, given its relative novelty. COVID-19 has brought about an unprecedented crisis to global health. Our trial started before, and closed during, the pandemic. We included a comparison between those who completed the trial before and those during the pandemic.

Methods

Participants

The study was conducted in Hong Kong. Participants were recruited from university mass emails, community posters, and online advertisements on various platforms. Eligible participants who completed the study received HKD$100 as a token of appreciation. Interested participants went through two stages of screening to confirm their eligibility (reported below and in the published protocol; Hui, Wong, Ma, Ho, & Chan, 2020). All participants provided written informed consent before proceeding to the screening.

A total of 2224 individuals completed the first stage of screening, which was a brief online self-report assessment. Eligible respondents were Hong Kong residents aged 18 years or above who were able to comprehend Chinese and type in Chinese or English, bothered by their sleep complaints for at least 3 months and for at least three nights per week, scored 8 or above on the Insomnia Severity Index (ISI) and 10 or above on the Patient Health Questionnaire (PHQ-9), able to access the Internet with smart devices using iOS or Android operational system, have a regularly used email address, and were able to provide informed consent.

The 685 respondents who met the above criteria were invited to proceed to the second stage of screening, which was a telephone diagnostic interview using the modified Chinese version of the Revised Clinical Schedule (CIS-R) (Chan et al., 2017). The interview identified the diagnosis of MDD, insomnia, as well as other comorbidities based on the International Statistical Classification of Diseases and Related Health Problems – Tenth Revision (ICD-10). The exclusion criteria included the diagnosis of psychosis or schizophrenia, past participation in the pilot trial of *proACT-S*, current and regular intake of prescribed psychiatric drugs for depression or insomnia, scored 2 or above on the suicidal ideation item of the Beck Depression Inventory-II

(BDI-II; Beck et al., 1996), report of current or past suicidal plans or acts in last 12 months, received psychological intervention on at least a monthly basis, or concurrent participation of any clinical trials targeting depression and/or insomnia. The prospective respondents ($n = 188$) who did not attend the diagnostic interview were excluded from the study.

For the diagnosis of insomnia, prospective participants were asked about their subjective experience of sleep disturbances and the additional criteria to quantify their sleep complaints as noted in DSM-5, such as the duration, severity, and frequency of their sleep problems (American Psychiatric Association, 2013; Chung et al., 2014; Sivertsen et al., 2021). The average total sleep time of the participants was <6.5 h. A CONSORT flow diagram is displayed in Fig. 1.

Trial design

In this two-arm parallel RCT, after the baseline assessment described above, participants were randomized to the treatment or the waitlist control group based on a 1:1 allocation ratio algorithm in the back-end of the smartphone application. Eligible participants completed the two scheduled assessments and 6-week self-help CBT-I treatment using *proACT-S*, which was developed by the principal investigator.

Eligible participants in the treatment group started the treatment immediately after randomization. They were invited to complete the second assessment, i.e. the *week 6 follow-up*, after the 6-week treatment. The third assessment, the *week 12 follow-up*, was administrated 6 weeks after the second assessment. Six weeks after the randomization, the waitlist control group was invited to complete the week 6 follow-up. They were then invited to begin the treatment and to complete the week 12 follow-up after the treatment.

This clinical trial was registered retrospectively at ClinicalTrials.gov (Identifier: NCT04228146), and the corresponding RCT protocol was published (Hui et al., 2020). The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects were approved by The University of Hong Kong prior to the data collection (EA1810026).

Blinding

The participants were told that the treatment start date would be randomly assigned to them by *proACT-S*, after they completed the baseline assessment. This was done to minimize participants' knowledge of their group assignment in the study. The principal investigator was blind to both the outcome assessments and group assignment. The research team was blind to the outcome assessments as they were all completed by the participants via *proACT-S*. Two research members were not blind to the group assignment as they had to send out reminder emails and messages to the participants to enhance treatment compliance. The data analyst was not blinded to group allocation. However, all the codes are included on OSF (https://osf.io/psk8h/?view_only=4b6e04f61ed24a7a93dfb28d5dbe9056).

CBT-I intervention

The treatment content was constructed based on the Chinese translated version (Yang, Huang, & Lin, 2008) of a CBT-I treatment manual (Morin & Espie, 2003). The details of the treatment content are reported elsewhere (Hui et al., 2020) and are included in the Supplementary material.

Withdrawal conditions

Participants were regarded as withdrawn from the study if they reported in any of the follow-up assessments: (1) having concurrent psychological treatment at least once per month; (2) taking prescribed psychiatric drugs such as antidepressants, tranquilizers, sleeping pills regularly; or (3) participating in any other academic studies or clinical trials related to insomnia and/or depression. These participants were allowed to continue to use *proACT-S* within the study period, but their study participation was regarded as withdrawn from the day they reported any of the abovementioned withdrawal conditions. As these participants could potentially produce bias in the treatment evaluation, we treated them as withdrawn. That is, their data available prior to withdrawal were analyzed, but the data since withdrawal were treated as missing. No participants were excluded from analyses in the post-randomization period.

Sample size calculation

A sample size of 199 was required to detect a small-sized effect of 0.2 (Ho et al., 2020) using mixed ANCOVA with 12 covariates, assuming a power of 80% and an α value of 5% (Hui et al., 2020). The study set an expected attrition rate of 30%, referencing the mean attrition rates reported in a meta-analysis of self-help CBT-I RCTs (Ho et al., 2020); we increased the target sample size to 285 to detect a small effect size (Cohen's $d = 0.2$) for the score differences in each of the primary outcomes from baseline to post-intervention.

Outcomes

Primary outcomes

Depression symptoms
The Chinese version of Center for Epidemiologic Studies Depression Scale (CES-D; Radloff, 1977) was used to measure the severity of depressive symptoms during the past week. Cronbach's α in this study across the assessments ranged from 0.83 to 0.92.

Insomnia severity
The Chinese version of ISI (Bastien, Vallières, & Morin, 2001) was used to assess the severity of insomnia symptoms and the associated daytime impairment over the past 2 weeks. Cronbach's α in this study ranged from 0.77 to 0.87.

Sleep quality
The Chinese version of Pittsburgh Sleep Quality Index (PSQI; Buysse, Reynolds, Monk, Berman, & Kupfer, 1989) was used to measure sleep quality and disturbances during the past month. Cronbach's α in this study ranged from 0.46 to 0.68, which is relatively low but consistent with previous studies ($\alpha = 0.55$, Chung & Tang, 2006; $\alpha = 0.66$, Guo, Sun, Liu, & Wu, 2016; $\alpha = 0.71$–0.72 for insomniacs, Tsai et al., 2005). There are debates regarding the dimensionality of PSQI, which potentially explains the variations in the scale's internal consistency (Manzar et al., 2018).

Fig. 1. A CONSORT flow diagram.

Secondary outcomes

Subjective health

The Chinese version of 12-item Short Form Survey (SF-12) Version 1 (Ware, Kosinski, & Keller, 1995) was used to measure subjective physical and mental health status.

Anxiety

The Chinese version of Hospital Anxiety and Depression Scale – Anxiety subscale (HADS; Zigmond & Snaith, 1983) was used to measure the severity of anxiety symptoms during the past week. Cronbach's α in this study ranged from 0.70 to 0.84.

Other measures

Treatment expectancy

The 6-item Credibility/Expectancy Questionnaire (Devilly & Borkovec, 2000) was modified to measure expectancy toward the treatment. It has been validated in CBT for people with depression or insomnia. Cronbach's α in this study ranged from 0.90 to 0.93.

Acceptability of treatment

The 26-item modified Participant Acceptability/Usability Rating Scale (Ben-Zeev et al., 2014) was used to evaluate the self-help treatment delivered via *proACT-S*.

Demographic information

Participants' age, education level, marital status, gender, and occupation were obtained in the first stage of screening process.

Clinical comorbidities

Participants' clinical comorbidities on generalized anxiety disorder, panic disorder, phobias, and obsessive-compulsive disorder as defined in the ICD-10 were assessed in the second stage of screening by telephone interview.

Adverse events

Questions checking on any potential adverse events in the follow-up questionnaires. Participants were given the contact information (phone and SMS) of the trial team as well as referral information in case additional support was needed.

Statistical analyses

An intention to treat analysis was conducted. Multilevel modeling was employed to evaluate the within-group and between-group effects, and to assess randomized conditions by time interaction. No imputation was performed as previous literature showed that multilevel modeling can handle high attrition without substantially reducing statistical power (Chakraborty & Gu, 2009). All analyses were conducted in *R*. The *lme4* package was used to run the multilevel models. Time points were nested within participants and a random participant-level intercept was included in the model. Randomized group, time, and their two-way interaction effect were included as fixed effects. Models were adjusted for baseline differences, if any, in demographic variables and comorbidity. A *p* value of <0.05 and 95% confidence interval were employed for main effects and interactions. Model fit was evaluated by the likelihood ratio test (LRT). Post-hoc *t* tests were performed to examine the between and within-group score differences. Sensitivity analyses were performed, including the

adjusted models with baseline differences in treatment expectancy, per-protocol analyses on those who accomplished a satisfactory number of modules, and a selection of subgroup on participants who were recruited during the COVID-19 as secondary analyses to check the robustness of the results. Post-hoc subgroup analyses were also performed on whether having a comorbid anxiety disorder would modify the treatment effect.

Results

Demographic information

Participant recruitment started in March 2019 and closed in March 2020. The trial began in May 2019 and ended in August 2020, after the expiration date for the last participant to complete the week 12 assessment. A total of 320 eligible participants (73% female; $M_{age} = 27.3$, S.D.$_{age} = 7.2$) passed the two stages of screening, completed the baseline assessment, and enrolled in the clinical trial. All participants completed high school, and 90% had attained some university education (Table 1). There were significant differences between the two groups in marital status ($\chi^2 = 6.33$, $p = 0.012$) and gender distribution ($\chi^2 = 9.93$, $p = 0.002$); both variables were included in all analyses as covariates. There were no significant differences between the groups in education background, occupation, clinical comorbidities, and age.

Among the eligible participants, 52% ($n = 167$, 65% female; $M_{age} = 27.3$, S.D.$_{age} = 7.3$) were randomized to the treatment group and 48% ($n = 153$, 81% female; $M_{age} = 27.3$, S.D.$_{age} = 7.2$) to the waitlist control group.

Preliminary analyses

No significant baseline differences were found between the groups on any outcome measures (Table 1). The intra-class correlations in the unconditional models ranged from 0.26 to 0.58, suggesting it was appropriate to conduct multilevel models for the outcome measures. Both the adjusted and unadjusted models gave comparable results on the treatment effects, the results of the former are presented. Multilevel modeling results and the corresponding LRTs for both primary and secondary outcomes are presented in Tables 2 and 3.

Primary outcomes

Depressive symptoms

In the multilevel model predicting depression symptoms, fixed effects for gender, marital status, and treatment condition were not significant. The week 6 follow-up time point [$B = -2.39$, S.E. = 0.72, $p < 0.001$, 95% CI (-3.81 to -0.99)] and the week 12 follow-up time point [$B = -9.28$, S.E. = 0.79, $p < 0.001$, 95% CI (-10.83 to -7.73)] showed significant negative associations with depression symptoms. Consistent with our hypothesis, the group by week 6 follow-up interaction showed significant association with depression symptoms $B = -6.72$, S.E. = 1.07, $p < 0.001$, 95% CI (-8.82 to -4.62) (Fig. 2). Follow-up simple effect analysis indicated that the treatment effect was significant at week 6 follow-up, $B = -7.73$, S.E. = 1.11, $p < 0.001$, 95% CI (-9.91 to -5.55).

Between-group comparison at week 6 follow-up was significant, in favor of the treatment group, $t(188) = -6.44$, $p < 0.001$, Cohen's $d = 0.86$, 95% CI (-10.11 to -5.37). In the within-group score comparison, the treatment group corresponded to a large

Table 1. Demographic background and individual characteristics at baseline ($N = 322$)

	Tx		WL				
	%	Mean (s.d.)	%	Mean (s.d.)	*t*	*p*	χ^2
Age (in years)		27.28 (7.25)		27.26 (7.22)	−0.017	0.986	
Gender						0.002	9.93
Female	65		81				
Education						0.944	0.94
At least some college	89		87				
Marital status						0.012	6.33
Married	16		7				
Anxiety disorder	65		63			0.724	0.125
Treatment expectancy							
Depression		0.19 (2.64)		−0.20 (2.76)	−1.302	0.194	
Insomnia		0.20 (2.72)		−0.23 (2.77)	−1.394	0.164	
Depressive symptoms		36.88 (8.06)		37.78 (7.80)	1.019	0.309	
Insomnia severity		18.41 (4.28)		18.52 (4.46)	0.224	0.823	
Poor sleep quality		12.39 (2.67)		12.14 (2.79)	−0.782	0.435	
Anxiety severity		12.04 (2.72)		12.19 (3.07)	0.454	0.650	
Subjective health (MCS)		26.32 (7.76)		26.26 (6.85)	−0.069	0.945	
Subjective health (PCS)		46.08 (8.94)		45.50 (8.34)	−0.603	0.547	

Note. Tx, treatment group; WL, waitlist control group. Depression severity was measured by the Center for Epidemiologic Studies Depression Scale. Insomnia severity was measured by the Insomnia Severity Index. Sleep quality was measured by the Pittsburgh Sleep Quality Index. Anxiety severity was measured by the Hospital Anxiety and Depression Scale – Anxiety subscale. Subjective health was measured by the SF-12 Version 1 (PCS, physical component score; MCS, mental component score).

effect before *v.* immediately after the treatment, $t(107) = 9.66$, $p < 0.001$, Cohen's $d = 0.93$, 95% Cl (7.18–10.89). The control group corresponded to a small effect before *v.* after the 6-week wait time, $t(137) = 4.64$, $p < 0.001$, Cohen's $d = 0.40$, 95% Cl (1.36–3.38) (Table 4).

Insomnia

In the multilevel model predicting insomnia severity, fixed effects for gender, marital status, and treatment condition were not significant. Both the week 6 follow-up time point [$B = −1.58$, s.e. $= 0.44$, $p < 0.001$, 95% CI (−2.44 to −0.71)] and week 12 follow-up time point [$B = −6.01$, s.e. $= 0.49$, $p < 0.001$, 95% CI (−6.96 to −5.06)] showed significant associations with insomnia severity. Consistent with our hypothesis, the treatment condition by week 6 follow-up interaction showed a significant association with insomnia severity, $B = −4.28$, s.e. $= 0.66$, $p < 0.001$, 95% CI (−5.58 to −2.99) (Fig. 2). Follow-up simple effect analysis indicated that the treatment effect was significant at week 6 follow-up, $B = −4.52$, s.e. $= 0.62$, $p < 0.001$, 95% Cl (−5.74 to −3.30).

Between-group comparison at week 6 follow-up was significant, in favor of the treatment group, $t(227) = −7.75$, $p < 0.001$, Cohen's $d = 1.00$, 95% Cl (−5.93 to −3.53). Both the treatment [$t(101) = 10.41$, $p < 0.001$, Cohen's $d = 1.03$, 95% Cl (4.40–6.47)] and control [$t(137) = 4.49$, $p < 0.001$, Cohen's $d = 0.38$, 95% Cl (0.91–2.35)] groups showed a significant drop in the insomnia severity at the week 6 follow-up; the control group corresponded to a small effect size in the change, while the treatment group yielded a large effect size in the reduction of insomnia (Table 4).

Sleep quality

In the multilevel model predicting sleep quality, fixed effects for gender, marital status, and treatment condition were not significant; while the week 6 follow-up [$B = −0.74$, s.e. $= 0.29$, $p = 0.011$, 95% CI (−1.31 to −0.17)] and the week 12 follow-up [$B = −2.80$, s.e. $= 0.32$, $p < 0.001$, 95% CI (−3.42 to −2.17)] showed significant associations with sleep quality. The treatment condition by week 6 follow-up interaction yielded a significant association on sleep quality, $B = −2.71$, s.e. $= 0.43$, $p < 0.001$, 95% CI (−3.56 to −1.87). Follow-up simple effect analysis showed that the treatment effect was significant at week 6 follow-up, $B = −2.42$, s.e. $= 0.40$, $p < 0.001$, 95% Cl (−3.21 to −1.63) (Fig. 2).

Between-group comparison at week 6 follow-up was significant, in favor of the treatment group, $t(206) = −6.74$, $p < 0.001$, Cohen's $d = 0.91$, 95% Cl (−3.34 to −1.83). In the within-group comparison, the treatment group showed a large difference before and after the treatment, $t(87) = 8.68$, $p < 0.001$, Cohen's $d = 0.93$, 95% Cl (2.42–3.85). The change in the control group corresponded to a small effect size, $t(116) = 2.41$, $p = 0.018$, Cohen's $d = 0.22$, 95% Cl (0.10–1.04) (Table 4).

Secondary outcomes

Anxiety symptoms

In the multilevel model predicting anxiety severity, fixed effects for gender, marital status, treatment condition, and the week 6 follow-up time point were not significant. The week 12 follow-up time point showed a significant association with anxiety symptoms, $B = −2.25$, s.e. $= 0.32$, $p < 0.001$, 95% CI (−2.88 to −1.63).

Table 2. Fixed effects and random effects estimates for multilevel models of predictors of outcome variables

Effect (fixed effects)	Estimate	s.e.	95% Cl LL	95% Cl UL	p
Model for depressive symptoms					
Intercept	38.346	1.068	36.261	40.432	<0.001
Gender	−0.684	0.981	−2.601	1.230	0.486
Marital status	−0.109	1.357	−2.759	2.540	0.936
Treatment condition (TC)	−1.006	1.008	−2.974	0.962	0.319
Week 6 follow-up (6-wk)	−2.399	0.723	−3.813	−0.986	<0.001
Week 12 follow-up (12-wk)	−9.279	0.792	−10.828	−7.732	<0.001
TC × 6-wk	−6.721	1.073	−8.820	−4.625	<0.001
TC × 12-wk	1.310	1.148	−0.934	3.553	0.254
Pseudo R^2	0.186				
Model for insomnia severity					
Intercept	18.887	0.566	17.782	19.993	<0.001
Gender	−0.492	0.508	−1.486	0.500	0.333
Marital status	0.530	0.706	−0.848	1.910	0.453
Treatment condition (TC)	−0.241	0.547	−1.310	0.827	0.659
Week 6 follow-up (6-wk)	−1.576	0.442	−2.439	−0.712	<0.001
Week 12 follow-up (12-wk)	−6.012	0.485	−6.962	−5.064	<0.001
TC × 6-wk	−4.281	0.660	−5.576	−2.994	<0.001
TC × 12-wk	−0.935	0.699	−2.304	0.430	0.182
Pseudo R^2	0.273				
Model for poor sleep quality					
Intercept	12.014	0.266	11.300	12.728	<0.001
Gender	0.149	0.324	−0.484	0.783	0.645
Marital status	−0.046	0.451	−0.927	0.836	0.919
Treatment condition (TC)	0.293	0.351	−0.393	0.978	0.405
Week 6 follow-up (6-wk)	−0.742	0.292	−1.312	−0.172	0.011
Week 12 follow-up (12-wk)	−2.798	0.320	−3.424	−2.174	<0.001
TC × 6-wk	−2.712	0.432	−3.558	−1.870	<0.001
TC × 12-wk	−0.542	0.455	−1.434	0.347	0.235
Pseudo R^2	0.120				
Model for anxiety severity					
Intercept	11.981	0.382	11.236	12.727	<0.001
Gender	0.212	0.344	−0.459	0.883	0.537
Marital status	0.558	0.475	−0.370	0.485	0.241
Treatment condition (TC)	−0.167	0.368	−0.885	0.552	0.651
Week 6 follow-up (6-wk)	0.270	0.293	−0.304	0.842	0.358
Week 12 follow-up (12-wk)	−2.254	0.320	−2.880	−1.629	<0.001
TC × 6-wk	−2.770	0.433	−3.615	−1.923	<0.001
TC × 12-wk	−0.002	0.462	−0.902	0.905	0.997
Pseudo R^2	0.127				

(*Continued*)

Table 2. (*Continued.*)

Effect (fixed effects)	Estimate	S.E.	95% CI LL	95% CI UL	p
Model of subjective health (physical)					
Intercept	46.540	1.042	44.506	48.576	<0.001
Gender	−1.149	0.966	−3.037	0.737	0.235
Marital status	−1.684	1.340	−4.302	0.933	0.210
Treatment condition (TC)	0.556	0.973	−1.343	2.455	0.568
Week 6 follow-up (6-wk)	0.764	0.652	−0.511	2.038	0.242
Week 12 follow-up (12-wk)	1.260	0.715	−0.138	2.657	0.079
TC × 6-wk	0.307	0.978	−1.605	2.219	0.754
TC × 12-wk	0.166	1.039	−1.864	2.199	0.873
Pseudo R^2	0.013				

Note. Male was the reference group for gender. Marital status was a binary variable, i.e. married *v.* not; single/no longer in marriage was the reference group. Treatment condition referred to the randomized group the participants were assigned to; waitlist control group was the reference group.

Table 3. Likelihood ratio tests between multilevel models for outcome variables

		df	deviance	AIC	BIC	$\Delta\chi^2$	Δdf	p
Depressive symptoms	Fixed intercept (null)	3	5592.3	5598.3	5612.2			
	Random intercept model	10	5344.3	5364.3	5410.8	247.94	7	<0.001
Insomnia severity	Fixed intercept (null)	3	4753.8	4759.8	4773.7			
	Random intercept model	10	4438.6	4458.6	4504.9	315.17	7	<0.001
Poor sleep quality	Fixed intercept (null)	3	3606.7	3612.7	3469.2			
	Random intercept model	10	3403.7	3423.7	3856.8	202.99	7	<0.001
Anxiety severity	Fixed intercept (null)	3	4007.0	4013.0	4027.0			
	Random intercept model	10	3867.4	3887.4	3933.8	139.67	7	<0.001
Subjective health (physical)	Fixed intercept (null)	3	5224.0	5230.0	5243.9			
	Random intercept model	10	5213.3	5233.3	5279.6	10.757	7	0.150

Note. AIC, Akaike information criterion; BIC, Bayesian information criterion.

Treatment condition by week 6 follow-up interaction yielded a significant association with anxiety symptoms, $B = -2.77$, S.E. = 0.43, $p < 0.001$, 95% CI (−3.62 to −1.92). Follow-up simple effect analysis found that the treatment effect was significant at week 6 follow-up, $B = -2.94$, S.E. = 0.41, $p < 0.001$, 95% CI (−3.74 to −2.13) (Fig. 2).

Between-group comparison at week 6 follow-up was significant, in favor of the treatment group, $t(209) = -6.30$, $p < 0.001$, Cohen's $d = 0.83$, 95% CI (−3.75 to −1.96). In the within-group comparison, the treatment group showed medium-to-large difference before and after the treatment, $t(107) = 6.69$, $p < 0.001$, Cohen's $d = 0.64$, 95% CI (1.71–3.16), while the control group showed no significant change (Table 4).

Subjective health

In the multilevel model predicting subjective physical health, fixed effects for gender, marital status, treatment condition, and the time points were not significant. Neither treatment group-by-time interaction terms were significant (all $ps > 0.05$; Fig. 2). Post-hoc t tests found no between and within-group differences across the follow-up time points on subjective physical health. Results on

subjective mental health are consistent with the findings on other mental health measures reported above (see Supplementary material).

Clinical significance

Depression

Adopting a cut-off score at 20 or above (Vilagut, Forero, Barbaglia, & Alonso, 2016), the percentage of participants in the treatment group scoring above the clinical threshold following the intervention decreased from 98% at baseline to 81% at the week 6 follow-up. The control group had a 1% decrease, from 99% at baseline to 98% at the week 6 follow-up. At the week 12 follow-up, the percentage in the treatment group scoring above the threshold sustained at 81% and the percentage in the control group reduced to 79% (Table 5).

Insomnia

With a cut-off score at 11 or above (Morin, Belleville, Bélanger, & Ivers, 2011), the percentage of participants in the treatment group meeting the clinical threshold decreased from 96% to 61% at the

Fig. 2. Marginal effects of treatment effect between treatment and control groups across time points. *Note.* Figure 2 displays the marginal effects in five main models. The plots accounted for the random effects in the multilevel models. The lower the score in depressive symptoms, insomnia severity, sleep quality, and anxiety severity, the better the condition of the participants. The higher the score in subjective health, the better the health condition of the participants. BL, baseline; 6 W FU, 6-week follow-up; 12 W FU, 12-week follow-up.

week 6 follow-up, while the control group found a decrease from 96% to 88%. At the week 12 follow-up, participants scoring above the threshold dropped from 61% to 52%. The control group saw a drop to 60% at the week 12 follow-up, after the given treatment (Table 5). We reported the results using 8 (i.e. in remission) as the cut-off score in online Supplementary Table S3.

Sleep quality

Using the cut-off score at above five (Buysse et al., 1989), the percentage of participants in the treatment group scoring above the poor sleep quality threshold decreased from 100% to 87%. The waitlist control group had a 1% decrease, from 100% at baseline to 99% at the week 6 follow-up. At the week 12 follow-up, the treatment group showed the maintenance of treatment effect with 87% scoring above the threshold. Among the control group, 84% scored above the threshold (Table 5).

Anxiety

Using the cut-off scores of 11–15 and 16–21 for moderate and severe anxiety symptoms, respectively (Snaith & Zigmond, 1994), the percentages of participants in the treatment group scoring above the clinical thresholds dropped from 61% at baseline to 32% for moderate anxiety symptoms, and from 11% at baseline to 5% for severe anxiety symptoms, at the week 6 follow up. The control group saw no improvement in the percentages of participants scoring above the threshold; those with moderate anxiety symptoms increased from 55% at baseline to 57% at the week 6 follow-up, and those with severe anxiety symptoms remained at 15% in both assessments. At the week 12 follow-up,

the clinical threshold percentages in the treatment group showed the maintenance of the treatment effect, where 31% had moderate anxiety symptoms and 5% had severe anxiety symptoms. The waitlist control group showed a reduction in anxiety severity after the given treatment, where the percentages of participants with moderate and severe anxiety symptoms dropped from 57% at the week 6 follow-up to 37% at the week 12 follow-up and from 15% at the week 6 follow-up to 4% at the week 12 follow-up, respectively (Table 5).

Dropout

Dropout varied from 1.2% to 37.7% at different time points (Fig. 1). The total dropout for the treatment and waitlist control groups was 37.7% and 26.8%, respectively.

Acceptability and usability

Over half of the participants found *proACT-S* easy to use. Nearly 90% of the participants found *proACT-S* clear and easy to understand. Over 60% of the participants were satisfied with the experience using *proACT-S* and nearly 70% would like to continue to use *proACT-S* if it was available. Half of the participants found it helpful in managing their symptoms. Taking a more conservative view, if we included all dropout participants as perceiving a negative view toward *proACT-S*, the perception of 'ease of use' was 50% or above. By-item ratings are reported in online Supplementary Table S4.

Table 4. Means, standard deviations, and post-hoc *t* tests across treatment group and control group and time

Outcome measures	n	Treatment group (Tx) Mean ± s.d.	Within-group effect size	n	Waitlist control group (WL) Mean ± s.d.	Within-group effect size	Tx v. WL p value	Between-group effect size
Depressive symptoms								
Baseline	167	36.88 ± 8.06		153	37.78 ± 7.80			
Week 6 follow-up	108	27.62 ± 10.53	0.929	138	35.36 ± 7.62	0.395	<0.001	0.859
Week 12 follow-up	95	28.65 ± 10.38	0.170	107	28.33 ± 9.81	0.228	0.820	0.032
Insomnia severity								
Baseline	167	18.41 ± 4.28		153	18.52 ± 4.46			
Week 6 follow-up	102	12.25 ± 4.50	1.030	138	16.99 ± 4.89	0.382	<0.001	1.000
Week 12 follow-up	95	11.22 ± 5.38	0.247	105	12.39 ± 5.53	0.695	0.131	0.214
Poor sleep quality								
Baseline	157	12.39 ± 2.67		137	12.14 ± 2.79			
Week 6 follow-up	94	8.79 ± 2.74	0.926	124	11.37 ± 2.89	0.222	<0.001	0.914
Week 12 follow-up	89	8.89 ± 3.28	0.078	96	9.28 ± 3.59	0.531	0.436	0.114
Anxiety severity								
Baseline	167	12.04 ± 2.72		153	12.19 ± 3.07			
Week 6 follow-up	108	9.52 ± 3.78	0.644	138	12.38 ± 3.18	0.124	<0.001	0.827
Week 12 follow-up	95	9.71 ± 3.66	0.080	107	9.89 ± 3.31	0.697	0.712	0.052
Subjective health (physical)								
Baseline	167	46.08 ± 8.94		153	45.50 ± 8.34			
Week 6 follow-up	104	46.96 ± 7.91	0.142	138	46.24 ± 8.87	0.105	0.508	0.085
Week 12 follow-up	95	47.63 ± 8.23	0.014	113	46.57 ± 8.37	0.083	0.363	0.128

Note. Tx, treatment group; WL, waitlist control group. The treatment group received self-help CBT-I treatment after baseline assessment and completed week 6 follow-up assessment after being given access to the CBT-I treatment content. The waitlist control group had to wait 6 weeks upon the completion of baseline assessment and received self-help CBT-I treatment after the completion of week 6 follow-up assessment. By week 12 follow-up assessment, both groups had been given access to the self-help CBT-I treatment.

Table 5. Percentages of participants with outcome scores above the clinical threshold across conditions and time

Outcome Measures	Above clinical threshold								
	Baseline			Week 6 follow-up			Week 12 follow-up		
	Tx	WL	χ^2	Tx	WL	χ^2	Tx	WL	χ^2
Depressive symptoms	98%	99%	0.000	81%	98%	17.217***	81%	79%	0.075
Insomnia severity	96%	96%	0.000	61%	88%	23.494***	52%	60%	1.114
Poor sleep quality	100%	100%	1.505	87%	99%	11.588***	87%	84%	0.182
Anxiety severity	72%	70%	0.065	37%	72%	29.580***	36%	41%	0.400

***$p < 0.001$.

Note. Tx, treatment group; WL, waitlist control group. The treatment group received the treatment after baseline assessment and completed week 6 follow-up assessment after being given access to the treatment content. The waitlist control group had to wait 6 weeks upon the completion of baseline assessment and received the treatment after the completion of week 6 follow-up assessment. By week 12 follow-up assessment, both groups had been given access to the treatment. Center for Epidemiologic Studies Depression Scale used cut-off score of ≥20. Insomnia Severity Index used cut-off score of ≥11. Pittsburgh Sleep Quality Index used cut-off score of >5. Hospital Anxiety and Depression Scale – Anxiety subscale used cut-off score of >10. For the anxiety severity, participants who endorse moderate and severe anxiety symptoms were grouped as 'beyond clinical threshold'.

Sensitivity analyses

First, to test whether treatment expectancy affected the primary outcomes of the study, adjusted models with the inclusion of treatment expectancy as a covariate were conducted. The results were similar to those reported above (online Supplementary Table S5). Second, the per-protocol analyses were performed, in which the reported multilevel models were conducted with a subsample that excluded those who did not complete at least five of the six treatment modules. The per-protocol analyses gave identical significant results (online Supplementary Table S6). Third, a subgroup of participants who started the study during the COVID-19 (52%), i.e. from February 2020 onwards, were

included in another set of multilevel model analyses to check the intervention effects. Similar results were found (online Supplementary Table S7). Subgroup analyses on participants having comorbid anxiety disorder found a similar significant interaction effect between treatment conditions and time. In the model of anxiety severity, having an anxiety disorder was not a factor impacting the treatment (online Supplementary Table S8). Baseline severity of depression and insomnia were included along with other baseline characteristics in simple regression analyses to observe the impacts on the maintenance of treatment effects. The initial treatment expectation on depression alleviation, gender, or having comorbid anxiety disorder could likely be a factor impacting the maintenance of the treatment effects (online Supplementary Table S9).

Harms

No adverse events, increased suicidal risk, nor significant deterioration in primary outcome measures was reported throughout the study.

Discussion

This RCT demonstrated the efficacy of a 6-week, non-assisted, self-help smartphone-based CBT-I in adults with both depression and insomnia. The effect was sustained at 6 weeks post-intervention. The treatment group demonstrated greater reductions in depressive, insomnia, and anxiety symptoms, as well as greater improvements in sleep quality at follow-up compared to the waitlist control group. A higher proportion of participants in the treatment group no longer met clinical cut-offs for depression, insomnia, and anxiety at post-treatment compared to the control group. Sensitivity analysis revealed that participants with and without anxiety reported similar treatment effects at week 6 and week 12 follow-ups. Similar improvements were seen in the control group after they were given the treatment.

This study added to the literature to show that smartphone-based self-help CBT-I can be efficacious in treating depression and that the treatment effect can be sustained to at least 6 weeks after the end of treatment. The effect size in improvement in depression was large and comparable to the previous results of CBT-I (Feng et al., 2020). While several studies have examined the efficacy of fully automated iCBT-I on depressive symptoms (Christensen et al., 2016; Glozier et al., 2019), ours is one of the first to test a fully automated smartphone app CBT-I on those with comorbid depression and insomnia.

The results should be interpreted in the context of the strengths and limitations of unguided self-help treatments, which, according to a network meta-analysis of the effect of CBT-D, is more efficacious than waitlist but less so than treatment modalities that have some input from a therapist (Cuijpers, Noma, Karyotaki, Cipriani, & Furukawa, 2019). The low-intensity nature of the treatment allows unguided self-help treatments to be readily disseminated, but, as our remission rate and adherence results suggest, it is far from being universally effective or helpful. As those suffering from depression would likely benefit from at least some forms of interactions with professionals (Newman, Szkodny, Llera, & Przeworski, 2011), we speculate that, if resources permit, augmenting the current treatment with therapist support would further improve outcomes.

Not surprisingly, post-treatment improvements in sleep symptoms were observed. The effect sizes of the improvement in insomnia and sleep quality are similar to those reported in previous studies (Feng et al., 2020; Horsch et al., 2017). In our treatment, sleep restriction was introduced at week 4, which is late than other iCBT-Is that reported the sequence of treatment components (Krieger et al., 2019; van der Zweerde, van Straten, Effting, Kyle, & Lancee, 2019). The effects of sleep restriction on sleep parameters would likely be more pronounced with time, especially if the recommendations are followed through. The adjusted sleep time would be reduced during sleep restriction, which explains the observed improvement in sleep efficiency at the follow-up assessments (reported in online Supplementary Table S10).

The findings of our secondary outcomes were largely consistent with previous studies of iCBT-I for anxiety (Ye et al., 2015). Our results suggest CBT-I can also help alleviate anxiety symptoms among those with depression and insomnia. Half of the participants' anxiety symptoms had reduced to mild to normal levels after the treatment and this improvement was sustained at the week 12 follow-up. The cognitive restructuring elements in our self-help treatment might have acted as an aid to alleviate anxiety symptoms, and hence helped to improve sleep. Further studies are needed to elucidate the relationship between anxiety symptoms and sleep improvement in self-help treatments.

Our participants saw improvement in subjective mental health but not physical health at the end of the 6-week intervention. The low-intensity treatment might not be sufficiently robust to bring changes in subjective physical health. This is consistent with previous RCTs reporting that CBT-I failed to demonstrate significant between-group improvement in physical health during the study period (Chakravorty et al., 2019; Espie et al., 2019; Siebmanns et al., 2021; Vedaa et al., 2020). However, better sleep is generally associated with better daytime functioning and subjective well-being (Chan, Poon, Leung, Lau, & Lau, 2018; Weinberg, Noble, & Hammond, 2016). It is plausible that if the participants continued to see improvements in their sleep and mental health, their subjective physical health may enhance.

The improvement in anxiety and subjective mental health is particularly noteworthy at the time of the COVID-19 pandemic. The overall acceptability and receptiveness of *proACT-S* were positive. These figures are similar to previous smartphone-based studies (Rost et al., 2017).

Taken together, *proACT-S* demonstrated efficacy in reducing depressive and insomnia symptoms without any human input. Balancing the need to reduce cost and to improve retention as well as to boost the treatment effect, future advancement of similar self-help treatments might consider including simple and automated means of providing users with reminders, feedback, and encouragement, such as using in-app notifications.

Implications

In many countries, the mental health burden overwhelms existing healthcare services. COVID-19 further widened the gap between the demand and supply of mental health services (Campion et al., 2020). Efficacious psychological treatments are available, but their accessibility is restricted by their resource-demanding nature, unaffordability, preference for self-reliance and alternative forms of support, and stigma toward mental health issues (Chung, Tse, Lee, Wong, & Chan, 2019; Corrigan et al., 2014; Hospital Authority, 2019; Shi et al., 2020). Furthermore, Kazlauskas, Eimontas, Olff, Zelviene, and Andersson (2020) indicated that populations with relatively high stigma toward mental health

tend to have higher adherence to self-help intervention and receive greater benefits from low-intensity and highly accessible treatments, such as Internet-based ones. Considering the relative imbalance between the demand and supply of mental health services, the relatively high degree of mental health stigma in Chinese communities, and the preference for self-reliant (Shi et al., 2020), *proACT-S* and other app-based self-help treatments might be able to help overcome some of the cultural barriers to access mental healthcare among Chinese-speakers. The study adds to the literature to demonstrate the efficacy of an app in Chinese, which can potentially provide support to a large group of patients.

proACT-S, like other CBT-I treatments, focuses on sleep but its efficacy was observable in depressive and anxiety symptoms. The bidirectionality of impact between sleep and mental health, especially the fact that sleep disturbance predisposes individuals to common mental disorders (Franzen & Buysse, 2008; Riemann, 2007; Vargas & Perlis, 2020), suggests that sleep-related intervention may be one of the means to promote psychological well-being. The sequence of improvement in depressive symptoms in response to transdiagnostic approaches such as sleep intervention is under ongoing investigation. There is evidence to suggest that sleep improvement established through CBT-I has a positive effect on the overall severity of depression (Cunningham & Shapiro, 2018). CBT is also believed to facilitate changes in information processing to ameliorate vegetative and cognitive symptoms of depression that, in turn, would contribute to the improvement of other depressive symptoms (Bhar et al., 2008). An RCT examining the efficacy of guided online CBT-I on depression reported promising effects on reducing preservative thinking (van der Zweerde et al., 2019), further suggesting the underlying mechanism of the influence of improved sleep. The specific contributions of different sleep outcomes impacting daytime functioning and particular depressive symptoms warrant further investigation (Wong et al., 2013).

Our study adds to the growing call for using sleep interventions, such as CBT-I, as a first-line treatment for common mental disorders (Blom et al., 2017; Hagatun et al., 2018; Ho et al., 2014; Thorndike et al., 2013; van der Zweerde et al., 2019). Smartphone-based treatments have lower barriers even compared with Internet-based treatments (Wilhelm et al., 2020). Our results suggest that *proACT-S* is not only efficacious but also well-received by some of its users. Rather than replacing the professional mental health services, *proACT-S* can be considered in conjunction with intensive treatment delivery by mental health professionals. It can, for example, be incorporated into a stepped care service delivery model as an early step in the treatment of common mental health problems (Ho et al., 2016).

Limitations

The current study has several limitations. First, the study participants were mostly young and well-educated. The findings have limited generalizability to the older and less educated population. To increasing the usability of *proACT-S* to those who are older or less-educated, further refinement of the app can be done, for example, by simplifying the contents and consider user feedback to further enhance the user experience.

Second, the study did not include a sleep diary as an outcome measure. Sleep diary could provide more precise and less memory-dependent sleep data than self-reported questionnaires (Ibáñez, Silva, & Cauli, 2018).

Third, beyond the baseline assessment stage, our study relied on self-report measures. Future research could include actigraphy or polysomnography for observing the changes in objective sleep parameters (Ibáñez et al., 2018) and conduct a follow-up clinical interview.

Fourth, the efficacy of the treatment was compared against a waitlist control group, as opposed to an active control group. Treatment studies with active control groups tend to show more modest effect sizes (e.g. Firth et al., 2017a, b). The use of a waitlist or no treatment condition as the control group is common in RCTs of self-help CBT-I (Ho et al., 2020). Future studies may include an inactive treatment, such as the monitoring of sleep using a sleep diary, in the control condition to enhance the validity of the evidence.

Fifth, while the treatment gains remained apparent at 6 weeks post-treatment, the lack of a longer-term follow-up limited our confidence in whether the treatment effect would sustain over time. van der Zweerde et al. (2019) reported that the positive effect of guided online CBT-I on depressive symptoms was maintained at a 6-month follow-up. Similarly, a study reported that participants continued to see treatment gain from iCBT-I on reduced depressive symptoms at 6-month, 1-year, and 3-year follow-up (Blom et al., 2017). Further work is needed to see *proACT-S* can also stand the test of time.

Last, this study had a high attrition rate; the figures are not incomparable with those reported in previous RCTs of smartphone-based intervention (mean attrition of 24.1% at short-term follow-up, Linardon & Fuller-Tyszkiewicz, 2020; mean attrition = 47.8% adjusted for publication bias, Torous, Lipschitz, Ng, & Firth, 2020). Several factors were identified to associate with a lower dropout rate in clinical trials of smartphone-based intervention, including integrating mood monitoring, providing monetary incentives, use of online enrollment, and provide human feedback/practice reminders (Torous et al., 2020). In the current study, we included a monetary incentive to attract and retain participants; this may hinder the generalizability of the findings as the incentive may have had an impact on adherence to the treatment and completion of outcome assessment.

Conclusion

This two-arm RCT study demonstrates the efficacy of *proACT-S*, an unguided smartphone-based CBT-I for depression. The transdiagnostic approach of sleep intervention for depression can help tackle the existing structural and cultural barriers of mental health needs. Because of its low cost, high accessibility, and minimal therapist involvement, we recommend considering a smartphone-based CBT-I such as *proACT-S* as a first-step intervention that can be disseminated at the community level to enhance the coverage of mental health services.

Conflict of interest. None.

References

American Psychiatric Association (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Arlington, VA: Author. doi: 10.1176/appi.books.9780890425596.

Census and Statistics Department (2017). Usage of information technology and the Internet by Hong Kong resident: 2000 to 2016. Available at: https://www.statistics.gov.hk/pub/B71711FB2017XXXXB0100.pdf.

Hospital Authority (2019). Waiting time for stable new case booking at specialist out-patient clinics. Retrieved October 09 from https://www.ha.org.hk/haho/ho/sopc/dw_wait_ls_eng.pdf.

Alaoui, S. E., Ljótsson, B., Hedman, E., Svanborg, C., Kaldo, V., & Lindefors, N. (2016). Predicting outcome in internet-based cognitive behaviour therapy for major depression: A large cohort study of adult patients in routine psychiatric care. *PLoS ONE*, 11(9), e0161191.

Baddeley, J. L., & Gros, D. F. (2013). Cognitive behavioral therapy for insomnia as a preparatory treatment for exposure therapy for posttraumatic stress disorder. *American Journal of Psychotherapy*, 67(2), 203–214.

Ballesio, A., Aquino, M. R. J. V., Feige, B., Johann, A. F., Kyle, S. D., Spiegelhalder, K., … Baglioni, C. (2018). The effectiveness of behavioural and cognitive behavioural therapies for insomnia on depressive and fatigue symptoms: A systematic review and network meta-analysis. *Sleep Medicine Reviews*, 37, 114–129.

Bastien, C. H., Vallières, A., & Morin, C. M. (2001). Validation of the Insomnia Severity Index as an outcome measure for insomnia research. *Sleep Medicine*, 2(4), 297–307.

Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. (1996). Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. *Journal of Personality Assessment*, 67(3), 588–597. https://doi.org/10.1207/s15327752jpa6703_13.

Bei, B., Asarnow, L. D., Krystal, A., Edinger, J. D., Buysse, D. J., & Manber, R. (2018). Treating insomnia in depression: Insomnia related factors predict long-term depression trajectories. *Journal of Consulting and Clinical Psychology*, 86(3), 282–293.

Ben-Zeev, D., Brenner, C. J., Begale, M., Duffecy, J., Mohr, D. C., & Mueser, K. T. (2014). Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. *Schizophrenia Bulletin*, 40(6), 1244–1253.

Bhar, S. S., Gelfand, L. A., Schmid, S. P., Gallop, R., DeRubeis, R. J., Hollon, S. D., … Beck, A. T. (2008). Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. *Journal of Affective Disorders*, 110(1–2), 161–166.

Blom, K., Jernelöv, S., Rück, C., Lindefors, N., & Kaldo, V. (2017). Three-year follow-up comparing cognitive behavioral therapy for depression to cognitive behavioral therapy for insomnia, for patients with both diagnoses. *Sleep*, 40(8), zsx108. doi: 10.1093/sleep/zsx108

Blom, K., Tillgren, H. T., Wiklund, T., Danlycke, E., Forssén, M., Söderström, A., … Kaldo, V. (2015). Internet-vs. group-delivered cognitive behavior therapy for insomnia: A randomized controlled non-inferiority trial. *Behaviour Research and Therapy*, 70, 47–55.

Buysse, D. J., Reynolds 3rd C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Research*, 28(2), 193–213.

Campion, J., Javed, A., Sartorius, N., & Marmot, M. (2020). Addressing the public mental health challenge of COVID-19. *The Lancet. Psychiatry*, 7(8), 657–659.

Chakraborty, H., & Gu, H.. (2009). *A Mixed Model Approach for Intent-to-Treat Analysis in Longitudinal Clinical Trials with Missing Values*. RTI Press publication No. MR-0009-0903. Research Triangle Park, NC: RTI International.

Chakravorty, S., Morales, K. H., Arnedt, J. T., Perlis, M. L., Oslin, D. W., Findley, J. C., & Kranzler, H. R. (2019). Cognitive behavioral therapy for insomnia in alcohol-dependent veterans: A randomized, controlled pilot study. *Alcoholism: Clinical and Experimental Research*, 43(6), 1244–1253.

Chan, C. S., Poon, C. Y. S., Leung, J. C. Y., Lau, K. N. T., & Lau, E. Y. Y. (2018). Delayed school start time is associated with better sleep, daytime functioning, and life satisfaction in residential high-school students. *Journal of Adolescence*, 66, 49–54.

Chan, W. C., Wong, C. S. M., Chen, E. Y. H., Ng, R. M. K., Hung, S. F., Cheung, E. F. C., … Lam, L. C. W. (2017). Validation of the Chinese version of the Revised Clinical Interview Schedule: Findings from Hong Kong Mental Morbidity Survey. *East Asian Archives of Psychiatry*, 27, 3–10.

Chin, W. Y., Chan, K. T. Y., Lam, C. L. K., Lam, T. P., & Wan, E. Y. F. (2015). Help-seeking intentions and subsequent 12-month mental health service use in Chinese primary care patients with depressive symptoms. *BMJ Open*, 5(1), e006730. doi: 10.1136/bmjopen-2014-006730

Christensen, H., Batterham, P. J., Gosling, J. A., Ritterband, L. M., Griffiths, K. M., Thorndike, F. P., … Mackinnon, A. J. (2016). Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): A randomised controlled trial. *The Lancet. Psychiatry*, 3(4), 333–341.

Chung, K. F., & Tang, M. K. (2006). Subjective sleep disturbance and its correlates in middle-aged Hong Kong Chinese women. *Maturitas*, 53(4), 396–404.

Chung, K. F., Tse, S., Lee, C. T., Wong, M. M. C., & Chan, W. M. (2019). Experience of stigma among mental health service users in Hong Kong: Are there changes between 2001 and 2017? *International Journal of Social Psychiatry*, 65(1), 64–72.

Chung, K. F., Yeung, W. F., Ho, Y. Y., Ho, L. M., Yung, K. P., Yu, Y. M., & Kwok, C. W. (2014). Validity and reliability of the Brief Insomnia Questionnaire in the general population in Hong Kong. *Journal of Psychosomatic Research*, 76(5), 374–379. doi: 10.1016/j.jpsychores.2014.03.002

Corrigan, P. W., Druss, B. G., & Perlick, D. A. (2014). The impact of mental illness stigma on seeking and participating in mental health care. *Psychological Science in the Public Interest*, 15(2), 37–70.

Cuijpers, P., Noma, H., Karyotaki, E., Cipriani, A., & Furukawa, T. A. (2019). Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: A network meta-analysis. *JAMA Psychiatry*, 76(7), 700–707.

Cunningham, J. E. A., & Shapiro, C. M. (2018). Cognitive behavioural therapy for insomnia (CBT-I) to treat depression: A systematic review. *Journal of Psychosomatic Research*, 106, 1–12.

Devilly, G. J., & Borkovec, T. D. (2000). Psychometric properties of the credibility/expectancy questionnaire. *Journal of Behavior Therapy and Experimental Psychiatry*, 31(2), 73–86.

Economides, M., Ranta, K., Nazander, A., Hilgert, O., Goldin, P. R., Raevuori, A., & Forman-Hoffman, V. (2019). Long-term outcomes of a therapist-supported, smartphone-based intervention for elevated symptoms of depression and anxiety: Quasiexperimental, pre-postintervention study. *Jmir Mhealth and Uhealth*, 7(8), e14284.

Espie, C. A., Emsley, R., Kyle, S. D., Gordon, C., Drake, C. L., Siriwardena, A. N., … Luik, A. I. (2019). Effect of digital cognitive behavioral therapy for insomnia on health, psychological well-being, and sleep-related quality of life: A randomized clinical trial. *JAMA Psychiatry*, 76(1), 21–30.

Fang, H., Tu, S., Sheng, J. F., & Shao, A. (2019). Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. *Journal of Cellular and Molecular Medicine*, 23(4), 2324–2332.

Feng, G. Y., Han, M., Li, X., Geng, L., & Miao, Y. C. (2020). The clinical effectiveness of cognitive behavioral therapy for patients with insomnia and depression: A systematic review and meta-analysis. *Evidence-Based Complementary and Alternative Medicine*, 2020, 8071821.

Firth, J., Torous, J., Nicholas, J., Carney, R., Pratap, A., Rosenbaum, S., & Sarris, J. (2017a). The efficacy of smartphone-based mental health interventions for depressive symptoms: A meta-analysis of randomized controlled trials. *World Psychiatry*, 16(3), 287–298.

Firth, J., Torous, J., Nicholas, J., Carney, R., Rosenbaum, S., & Sarris, J. (2017b). Can smartphone mental health interventions reduce symptoms of anxiety? A meta-analysis of randomized controlled trials. *Journal of Affective Disorders*, 218, 15–22.

Franzen, P. L., & Buysse, D. J. (2008). Sleep disturbances and depression: Risk relationships for subsequent depression and therapeutic implications. *Dialogues in Clinical Neuroscience*, 10(4), 473–781.

Glozier, N., Christensen, H., Griffiths, K. M., Hickie, I. B., Naismith, S. L., Biddle, D., … Ritterband, L. (2019). Adjunctive Internet-delivered cognitive behavioural therapy for insomnia in men with depression: A randomised controlled trial. *Australian and New Zealand Journal of Psychiatry*, 53(4), 350–360.

Goldstein, A. (1962). *Therapist and patient expectancies in psychotherapy.* New York: Macmillan.

Guo, S., Sun, W., Liu, C., & Wu, S. (2016). Structural validity of the Pittsburgh Sleep Quality Index in Chinese undergraduate students. *Frontiers in Psychology*, 7, 1126.

Hagatun, S., Vedaa, Ø., Harvey, A. G., Nordgreen, T., Smith, O. R. F., Pallesen, S., … Sivertsen, B. (2018). Internet-delivered cognitive-behavioral therapy for insomnia and comorbid symptoms. *Internet Interventions*, 12, 11–15.

Hanson, K., Webb, T. L., Sheeran, P., & Turpin, G. (2016). Attitudes and preferences towards self-help treatments for depression in comparison to psychotherapy and antidepressant medication. *Behavioural and Cognitive Psychotherapy*, 44(2), 129–139.

Harris, L. M., Huang, X., Linthicum, K. P., Bryen, C. P., & Ribeiro, J. D. (2020). Sleep disturbances as risk factors for suicidal thoughts and behaviours: A meta-analysis of longitudinal studies. *Scientific Reports*, 10, 13888.

Harvey, A. G., Murray, G., Chandler, R. A., & Soehner, A. (2011). Sleep disturbance as transdiagnostic: Consideration of neurobiological mechanisms. *Clinical Psychology Review*, 31(2), 225–235.

Ho, F. Y. Y., Chan, C. S., Lo, W. Y., & Leung, J. C. Y. (2020). The effect of self-help cognitive behavioral therapy for insomnia on depressive symptoms: An updated meta-analysis of randomized controlled trials. *Journal of Affective Disorders*, 265, 287–304.

Ho, F. Y. Y., Chung, K. F., Yeung, W. F., Ng, T. H. Y., & Cheng, S. K. W. (2014). Weekly brief phone support in self-help cognitive behavioral therapy for insomnia disorder: Relevance to adherence and efficacy. *Behaviour Research and Therapy*, 63, 147–156.

Ho, F. Y. Y., Yeung, W. F., Ng, T. H. Y., & Chan, C. S. (2016). The efficacy and cost-effectiveness of stepped care prevention and treatment for depressive and/or anxiety disorders: A systematic review and meta-analysis. *Scientific Reports*, 6, 29281.

Horsch, C. H. G., Lancee, J., Griffioen-Both, F., Spruit, S., Fitrianie, S., Neerincx, M. A., … Brinkman, W. P. (2017). Mobile phone-delivered cognitive behavioral therapy for insomnia: A randomized waitlist controlled trial. *Journal of Medical Internet Research*, 19(4), e70.

Hui, V. K. Y., Wong, C. Y. F., Ma, E. K. Y., Ho, F. Y. Y., & Chan, C. S. (2020). Treating depression with a smartphone-delivered self-help cognitive behavioral therapy for insomnia: Study protocol for a parallel group randomized controlled trial. *Trials*, 21, 843.

Ibáñez, V., Silva, J., & Cauli, O. (2018). A survey on sleep assessment methods. *Peer-reviewed Journal*, 6, e4849.

Kaufman, J., & Charney, D. (2000). Comorbidity of mood and anxiety disorders. *Depression and Anxiety*, 12, 69–76.

Kazlauskas, E., Eimontas, J., Olff, M., Zelviene, P., & Andersson, G. (2020). Adherence predictors in internet-delivered self-help intervention for life stressors-related adjustment disorder. *Frontiers in Psychiatry*, 11, 137.

Krieger, T., Urech, A., Duss, S. B., Blättler, L., Schmitt, W., Gast, H., … Berger, T. (2019). A randomized controlled trial comparing guided internet-based multi-component treatment and internet-based guided sleep restriction treatment to care as usual in insomnia. *Sleep Medicine*, 62, 43–52.

Lekander, M., Andreasson, A. N., Kecklund, G., Ekman, R., Ingre, M., Akerstedt, T., & Axelsson, J. (2013). Subjective health perception in healthy young men changes in response to experimentally restricted sleep and subsequent recovery sleep. *Brain, Behavior, and Immunity*, 34, 43–46.

Linardon, J., Cuijpers, P., Carlbring, P., Messer, M., & Fuller-Tyszkiewicz, M. (2019). The efficacy of app-supported smartphone interventions for mental health problems: A meta-analysis of randomized controlled trials. *World Psychiatry*, 18(3), 325–336.

Linardon, J., & Fuller-Tyszkiewicz, M. (2020). Attrition and adherence in smartphone-delivered interventions for mental health problems: A systematic and meta-analytic review. *Journal of Consulting and Clinical Psychology*, 88(1), 1–13.

Liu, R. T., Steele, S. J., Hamilton, J. L., Do, Q. B. P., Furbish, K., Burke, T. A., … Gerlus, N. (2020). Sleep and suicide: A systematic review and meta-analysis of longitudinal studies. *Clinical Psychology Review*, 81, 101895. doi: 10.1016/j.cpr.2020.101895

Mantani, A., Kato, T., Furukawa, T. A., Horikoshi, M., Imai, H., Hiroe, T., … Kawanishi, N. (2017). Smartphone cognitive behavioral therapy as an adjunct to pharmacotherapy for refractory depression: Randomized controlled trial. *Journal of Medical Internet Research*, 19(11), e373.

Manzar, M. D., BaHammam, A. S., Hameed, U. A., Spence, D. W., Pandi-Perumal, S. R., Moscovitch, A., & Streiner, D. L. (2018). Dimensionality of the Pittsburgh Sleep Quality Index: A systematic review. *Health and Quality of Life Outcomes*, 16(1), 89.

McClintock, S. M., Husain, M. M., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Trivedi, M. H., … Rush, A. J. (2011). Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. *Journal of Clinical Psychopharmacology*, 31(2), 180–186.

Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). The Insomnia Severity Index: Psychometric indicators to detect insomnia cases and evaluate treatment response. *Sleep*, 34(5), 601–608.

Morin, C. M., & Espie, C. A. (2003). *Insomnia: A clinical guide to assessment and treatment.* New York: Kluwer Academic/Plenum.

Newman, M. G., Szkodny, L. E., Llera, S. J., & Przeworski, A. (2011). A review of technology-assisted self-help and minimal contact therapies for anxiety and depression: Is human contact necessary for therapeutic efficacy? *Clinical Psychology Review*, 31(1), 89–103.

Parker, G., Cheah, Y. C., & Roy, K. (2001). Do the Chinese somatize depression? A cross-cultural study. *Social Psychiatry and Psychiatric Epidemiology*, 36(6), 287–293.

Radloff, L. S. (1977). The CES-D scale: A self-report depression scale for research in the general population. *Applied Psychological Measurement*, 1(3), 385–401.

Riemann, D. (2007). Insomnia and comorbid psychiatric disorders. *Sleep Medicine*, 8(Suppl 4), S15–S20.

Rost, T., Stein, J., Löbner, M., Kersting, A., Luck-Sikorski, C., & Riedel-Heller, S. G. (2017). User acceptance of computerized cognitive behavioral therapy for depression: Systematic review. *Journal of Medical Internet Research*, 19(9), e309.

Salari, N., Hosseinian-Far, A., Jalali, R., Vaisi-Raygani, A., Rasoulpoor, S., Mohammadi, M., … Khaledi-Paveh, B. (2020). Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. *Globalization and Health*, 16(1), 57.

Santoft, F., Axelsson, E., Öst, L.-G., Hedman-Lagerlöf, M., Fust, J., & Hedman-Lagerlöf, E. (2019). Cognitive behaviour therapy for depression in primary care: Systematic review and meta-analysis. *Psychological Medicine*, 49(8), 1266–1274.

Segal, S. P., Hodges, J. Q., & Hardiman, E. R. (2002). Factors in decisions to seek help from self-help and co-located community mental health agencies. *American Journal of Orthopsychiatry*, 72(2), 241–249.

Shi, W., Shen, Z. Z., Wang, S. Y., & Hall, B. J. (2020). Barriers to professional mental health help-seeking among Chinese adults: A systematic review. *Frontiers in Psychiatry*, 11, 442. doi: 10.3389/fpsyt.2020.00442

Siebmanns, S., Johansson, P., Ulander, M., Johansson, L., Andersson, G., & Broström, A. (2021). The effect of nurse-led Internet-based cognitive behavioural therapy for insomnia on patients with cardiovascular disease: A randomized controlled trial with 6-month follow-up. *Nursing Open*, 8(4), 1755–1768.

Sivertsen, B., Pallesen, S., Friborg, O., Nilsen, K. B., Bakke, Ø. K., Goll, J. B., & Hopstock, L. A. (2021). Sleep patterns and insomnia in a large population-based study of middle-aged and older adults: The Tromsø study 2015–2016. *Journal of Sleep Research*, 30(1), e13095.

Snaith, R. P., & Zigmond, A. S. (1994). *HADS: Hospital anxiety and depression scale.* Windsor, Berkshire, UK: NFER-Nelson.

Tan, S. L., Storm, V., Reinwand, D. A., Wienert, J., de Vries, H., & Lippke, S. (2018). Understanding the positive associations of sleep, physical activity, fruit and vegetable intake as predictors of quality of life and subjective health across age groups: A theory based, cross-sectional web-based study. *Frontiers in Psychology*, 9, 977.

Thorndike, F. P., Ritterband, L. M., Gonder-Frederick, L. A., Lord, H. R., Ingersoll, K. S., & Morin, C. M. (2013). A randomized controlled trial of

an internet intervention for adults with insomnia: Effects on comorbid psychological and fatigue symptoms. *Journal of Clinical Psychology*, *69*(10), 1078–1093.

Torous, J., Lipschitz, J., Ng, M., & Firth, J. (2020). Dropout rates in clinical trials of smartphone apps for depressive symptoms: A systematic review and meta-analysis. *Journal of Affective Disorders*, *263*, 413–419.

Tsai, P. S., Wang, S. Y., Wang, M. Y., Su, C. T., Yang, T. T., Huang, C. J., & Fang, S. C. (2005). Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects. *Quality of Life Research*, *14*(8), 1943–1952.

Tsuno, N., Besset, A., & Ritchie, K. (2005). Sleep and depression. *Journal of Clinical Psychiatry*, *66*(10), 1254–1269.

van der Zweerde, T., van Straten, A., Effting, M., Kyle, S. D., & Lancee, J. (2019). Does online insomnia treatment reduce depressive symptoms? A randomized controlled trial in individuals with both insomnia and depressive symptoms. *Psychological Medicine*, *49*(3), 501–509.

Vargas, I., & Perlis, M. L. (2020). Insomnia and depression: Clinical associations and possible mechanistic links. *Current Opinion in Psychiatry*, *34*, 95–99.

Vedaa, Ø, Kallestad, H., Scott, J., Smith, O. R. F., Pallesen, S., Morken, G., … Sivertsen, B. (2020). Effects of digital cognitive behavioural therapy for insomnia on insomnia severity: A large-scale randomised controlled trial. *The Lancet Digital Health*, *2*(8), e397–e406.

Vilagut, G., Forero, C. G., Barbaglia, G., & Alonso, J. (2016). Screening for depression in the general population with the center for epidemiologic studies depression (CES-D): A systematic review with meta-analysis. *PLoS ONE*, *11*(5), e0155431.

Ware, J. E., Kosinski, M., & Keller, S. D. (1995). SF-12: How to score the SF-12 physical and mental health summary scales. QualityMetric Incorporated.

Weinberg, M. K., Noble, J. M., & Hammond, T. G. (2016). Sleep well feel well: An investigation into the protective value of sleep quality on subjective well-being. *Australian Journal of Psychology*, *68*, 91–97.

Wilhelm, S., Weingarden, H., Ladis, I., Braddick, V., Shin, J., & Jacobson, N. C. (2020). Cognitive-behavioral therapy in the digital age: Presidential address. *Behavior Therapy*, *51*(1), 1–14.

Wong, M. L., Lau, E. Y. Y., Wan, J. H. Y., Cheung, S. F., Hui, C. H., & Mok, D. S. Y. (2013). The interplay between sleep and mood in predicting academic functioning, physical health and psychological health: A longitudinal study. *Journal of Psychosomatic Research*, *74*(4), 271–277.

Yang, J. M., Huang, Y. L., & Lin, S. W. (2008). *Insomnia: A clinical guide to assessment and treatment*. Taiwan: Psychological Publishing Co. (in Chinese)

Ye, Y. Y., Zhang, Y. F., Chen, J., Liu, J., Li, X. J., Liu, Y. Z., … Jiang, X. J. (2015). Internet-based cognitive behavioral therapy for insomnia (ICBT-i) improves comorbid anxiety and depression – A meta-analysis of randomized controlled trials. *PLoS ONE*, *10*(11), e0142258.

Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. *Acta Psychiatrica Scandinavica*, *67*(6), 361–370.